Diabetes, cardiovascular risk and nephropathy

Cardiology Clinics

Volumn 28, Issue 3, 2010, Pages 467-475

  Hahr, Allison J ^a   Molitch, Mark E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Cardiovascular risk; Diabetes mellitus; Nephropathy; Risk reduction

Indexed keywords

ATORVASTATIN; GLICLAZIDE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PRAVASTATIN; SULFONYLUREA;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE COURSE; DYSLIPIDEMIA; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SMOKING CESSATION; WEIGHT REDUCTION; CARDIOVASCULAR DISEASES; COMORBIDITY; COMPLICATION; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; FEMALE; HYPERGLYCEMIA; HYPERTENSION; MALE; PREVALENCE; RISK FACTOR;

CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; MALE; PREVALENCE; RISK FACTORS; SMOKING CESSATION; WEIGHT LOSS;

EID: 77954503845     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2010.04.006     Document Type: Review

References (63)

1. Roglic G., Unwin N., Bennett P.H., et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 2005, 28(9):2130-2135.
2. American Diabetes Association Standards of Medical Care in Diabetes-2010. Diabetes Care 2010, 33(Suppl 1):S11-S61.
3. Thom T., Haase N., Rosamond W., et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113(6):e85-151.
4. Lloyd-Jones D.M., Leip E.P., Larson M.G., et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006, 113(6):791-798.
5. Fox C.S., Pencina M.J., Wilson P.W., et al. Lifetime risk of cardiovascular disease among individuals with and without diabetes stratified by obesity status in the Framingham heart study. Diabetes Care 2008, 31(8):1582-1584.
6. Hu F.B., Stampfer M.J., Haffner S.M., et al. Elevated risk of cardiovascular disease before clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25(7):1129-1134.
7. Chun B.Y., Dobson A.J., Heller R.F. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care 1997, 20(5):704-708.
8. Mukamal K.J., Nesto R.W., Cohen M.C., et al. Impact of diabetes on long-term survival after acute myocardial infarction: comparability of risk with prior myocardial infarction. Diabetes Care 2001, 24(8):1422-1427.
9. Huxley R., Barzi F., Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006, 332(7533):73-78.
10. Donahoe S.M., Stewart G.C., McCabe C.H., et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007, 298(7):765-775.
11. Hu F.B., Stampfer M.J., Solomon C.G., et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med 2001, 161(14):1717-1723.
12. Gregg E.W., Gu Q., Cheng Y.J., et al. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med 2007, 147(3):149-155.
13. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339(4):229-234.
14. Whiteley L., Padmanabhan S., Hole D., et al. Should diabetes be considered a coronary heart disease risk equivalent? results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 2005, 28(7):1588-1593.
15. Juutilainen A., Lehto S., Ronnemaa T., et al. Type 2 diabetes as a " coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005, 28(12):2901-2907.
16. Schramm T.K., Gislason G.H., Kober L., et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008, 117(15):1945-1954.
17. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
18. Jensen T., Borch-Johnsen K., Kofoed-Enevoldsen A., et al. Coronary heart disease in young type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy: incidence and risk factors. Diabetologia 1987, 30(3):144-148.
19. Valmadrid C.T., Klein R., Moss S.E., et al. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000, 160(8):1093-1100.
20. Tonelli M., Keech A., Shepherd J., et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005, 16(12):3748-3754.
21. Coresh J., Longenecker J.C., Miller E.R., et al. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol 1998, 9(Suppl 12):S24-S30.
22. Adler A.I., Stevens R.J., Manley S.E., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63(1):225-232.
23. Borch-Johnsen K., Andersen P.K., Deckert T. The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1985, 28(8):590-596.
24. Dinneen S.F., Gerstein H.C. The association of microalbuminuria and mortality in noninsulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997, 157(13):1413-1418.
25. Fonseca V.A. Risk factors for coronary heart disease in diabetes. Ann Intern Med 2000, 133(2):154-156.
26. Varma R., Garrick R., McClung J., et al. Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease. Cardiol Rev 2005, 13(2):98-107.
27. O'Brien T., Nguyen T.T., Zimmerman B.R. Hyperlipidemia and diabetes mellitus. Mayo Clin Proc 1998, 73(10):969-976.
28. Ginsberg H.N. Review: efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006, 91(2):383-392.
29. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360(9326):7-22.
30. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364(9435):685-696.
31. Collins R., Armitage J., Parish S., et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361(9374):2005-2016.
32. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350(15):1495-1504.
33. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352(14):1425-1435.
34. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004, 44(3):720-732.
35. Molitch M.E. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 2006, 1(5):1090-1099.
36. Wanner C., Krane V., Marz W., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353(3):238-248.
37. Fellstrom B.C., Jardine A.G., Schmieder R.E., et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009, 360(14):1395-1407.
38. KDOQI KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007, 49(2 Suppl 2):S12-154.
39. Bakris G.L., Williams M., Dworkin L., et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis Sep 2000, 36(3):646-661.
40. Klag M.J., Whelton P.K., Randall B.L., et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996, 334(1):13-18.
41. Perry H.M., Miller J.P., Fornoff J.R., et al. Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995, 25(4 Pt 1):587-594.
42. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
43. American Diabetes Association Standards of medical care in diabetes-2008. Diabetes Care 2008, 31(Suppl 1):S12-S54.
44. Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004, 141(6):421-431.
45. Gerstein H.C., Pogue J., Mann J.F., et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and nondiabetic participants in the HOPE study: a prospective epidemiologic analysis. Diabetologia 2005, 48(9):1749-1755.
46. Selvin E., Coresh J., Golden S.H., et al. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 2005, 165(16):1910-1916.
47. Ceriello A., Hanefeld M., Leiter L., et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004, 164(19):2090-2095.
48. DECODE Study Group, the European Diabetes Epidemiology Group Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001, 161(3):397-405.
49. Saydah S.H., Miret M., Sung J., et al. Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 2001, 24(8):1397-1402.
50. Raz I., Wilson P.W., Strojek K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009, 32(3):381-386.
51. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993, 329(14):977-986.
52. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353(25):2643-2653.
53. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):837-853.
54. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589.
55. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854-865.
56. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003, 348(5):383-393.
57. Gaede P., Lund-Andersen H., Parving H.H., et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580-591.
58. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
59. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
60. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360(2):129-139.
61. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009, 53(3):298-304.
62. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37(12):1595-1607.
63. Frye R.L., August P., Brooks M.M., et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360(24):2503-2515.